The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Trastuzumab plus capecitabine with or without pertuzumab in patients with HER2-positive MBC whose disease has progressed during or following trastuzumab-based therapy for first-line metastatic disease: A multicenter, randomized, two-arm, phase II study (PHEREXA).
M. Munoz-Mateu
Other Remuneration - Congress assistance and conference honoraria
A. Urruticoechea
Expert Testimony - Roche (U)
R. Separovic
No relevant relationships to disclose
J. Erfán
No relevant relationships to disclose
T. D. Bachelot
Consultant or Advisory Role - Roche (U)
Research Funding - Roche
J. Canon
Research Funding - Grand Hopital de Charleroi
N. Kovalenko
No relevant relationships to disclose
E. Staroslawska
No relevant relationships to disclose
B. Pikó
No relevant relationships to disclose
C. Veyret
No relevant relationships to disclose
O. Pribylova
No relevant relationships to disclose
D. L. Ciule
No relevant relationships to disclose
J. Ratnayake
Employment or Leadership Position - Roche
S. Das
Employment or Leadership Position - Roche
K. Mayne
Employment or Leadership Position - Roche
G. Ross
Employment or Leadership Position - Roche
Stock Ownership - Roche